Cytori Therapeutics Inc (NASDAQ:CYTX) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Tuesday, August 1st.
A number of other analysts have also commented on the stock. B. Riley reaffirmed a “neutral” rating on shares of Cytori Therapeutics in a report on Sunday, July 30th. Zacks Investment Research lowered shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Maxim Group set a $10.00 target price on shares of Cytori Therapeutics and gave the stock a “buy” rating in a report on Monday, July 10th.
Cytori Therapeutics (NASDAQ:CYTX) traded down 1.5568% during midday trading on Tuesday, hitting $0.3225. The stock had a trading volume of 421,660 shares. The stock’s 50-day moving average is $0.69 and its 200-day moving average is $1.16. The company’s market cap is $11.20 million. Cytori Therapeutics has a one year low of $0.31 and a one year high of $2.29.
Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.02. Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.23 million. During the same period in the prior year, the firm posted ($0.43) EPS. Cytori Therapeutics’s revenue was down 18.2% on a year-over-year basis. Equities analysts predict that Cytori Therapeutics will post ($0.60) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/08/19/cytori-therapeutics-inc-cytx-downgraded-to-strong-sell-at-valuengine-updated-updated.html.
An institutional investor recently raised its position in Cytori Therapeutics stock. Vanguard Group Inc. boosted its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 612,304 shares of the biotechnology company’s stock after buying an additional 275,653 shares during the period. Vanguard Group Inc. owned about 1.89% of Cytori Therapeutics worth $674,000 at the end of the most recent quarter. 10.01% of the stock is owned by institutional investors.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Cytori Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytori Therapeutics Inc and related companies.